-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Monday's Intraday Session
Share
Listen to the news

Gainers

  • Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million.
  • Advanced Biomed (NASDAQ:ADVB) stock moved upwards by 51.88% to $7.64. The market value of their outstanding shares is at $8.2 million.
  • Axe Compute (NASDAQ:AGPU) stock moved upwards by 26.83% to $8.71. The market value of their outstanding shares is at $78.2 million.
  • Neuronetics (NASDAQ:STIM) stock increased by 25.3% to $2.03. The company's market cap stands at $112.7 million.
  • Exicure (NASDAQ:XCUR) stock rose 17.62% to $1.98. The market value of their outstanding shares is at $10.7 million.
  • Barinthus Biotherapeutics (NASDAQ:BRNS) stock increased by 13.6% to $0.63. The market value of their outstanding shares is at $22.6 million.

Losers

  • Karyopharm Therapeutics (NASDAQ:KPTI) shares declined by 28.9% to $6.76 during Monday's regular session. The market value of their outstanding shares is at $215.5 million.
  • Pomdoctor (NASDAQ:POM) stock declined by 27.89% to $0.81. The company's market cap stands at $134.6 million.
  • Dare Bioscience (NASDAQ:DARE) shares declined by 27.05% to $1.43. The company's market cap stands at $29.3 million.
  • BioVie (NASDAQ:BIVI) shares decreased by 19.46% to $1.45. The company's market cap stands at $13.5 million.
  • Valion Bio (NASDAQ:VBIO) stock fell 17.76% to $0.42. The company's market cap stands at $1.6 million.
  • GlucoTrack (NASDAQ:GCTK) stock fell 17.56% to $0.41. The company's market cap stands at $3.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending